- Home
- GSK vs BMY Comparison
GSK vs BMY Comparison
Compare GSK & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GSK | BMY |
|---|---|---|
| Founded | 1715 | 1887 |
| Country | United Kingdom | United States |
| Employees | 66841 | 32500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7B | 115.3B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GSK | BMY |
|---|---|---|
| Price | $48.99 | $54.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 15 |
| Target Price | N/A | ★ $61.73 |
| AVG Volume (30 Days) | 3.2M | ★ 8.8M |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | 3.40% | ★ 4.38% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $4.19 | N/A |
| P/E Ratio | $32.75 | ★ $17.26 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.45 | $42.52 |
| 52 Week High | $61.70 | $62.89 |
Technical Indicators
Market Signals| Indicator | GSK | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 34.11 |
| Support Level | $48.99 | $53.88 |
| Resistance Level | $49.15 | $55.04 |
| Average True Range (ATR) | 0.78 | 1.39 |
| MACD | 0.01 | -0.27 |
| Stochastic Oscillator | 12.01 | 4.88 |
Price Performance
Historical ComparisonAbout GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
About BMY Bristol-Myers Squibb Company
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.